Key result
Low-dose rivaroxaban plus ASA linked to ~20% fewer angina attacks over 10 weeks.
Why the study?
The effect of low-dose rivaroxaban on quality of life and clinical manifestations in patients with FC II-III stable angina was not well evaluated.
Does low-dose rivaroxaban combined with aspirin reduce angina attacks and improve quality of life in patients with ischemic heart disease and stable angina?
Cohort (n=26)
Does low-dose rivaroxaban combined with aspirin reduce angina attacks and improve quality of life in patients with ischemic heart disease and stable angina?
Low-dose rivaroxaban combined with aspirin may reduce angina frequency and improve quality of life in patients with stable ischemic heart disease.
Answers are grounded in this paper and cite their sources.
May improve QoL in stable angina; hypothesis-generating and requires randomized confirmation before practice change.
Aim To evaluate the effect of low-dose rivaroxaban on quality of life of patients and clinical manifestations of functional class (FC) II-III stable angina.Material and methods 26 patients with ischemic heart disease (IHD) with FC II-III stable angina, who were newly prescribed rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg, were followed for 10 weeks. During the first (before the beginning of treatment) and the last weeks of study, patients kept diaries, in which they reported angina attacks and short-acting nitrate intake, filled in an angina questionnaire (SAQ), and underwent electrocardiogram (ECG) Holter monitoring (HM).Results The treatment was associated with decreases in the frequency of angina attacks (by 19.5 %; р=0.027) and the number of taken short-acting nitrate pills (by 17.1 %; р=0.021) and an improvement of quality of life according to stability scales (р=0.042). Data from ECG HM showed decreases in the number and duration of ischemic episodes (p≤0.05).Conclusion The treatment of IHD patients with rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg for 2 mos. was associated with decreased frequency of angina attacks, reduced requirement for short-acting nitrate, and with improvement of quality of life.
No takes yet. Share an insight, caveat, or question.
Некрасов et al. (2021) conducted a cohort in Ischemic heart disease with FC II-III stable angina (n=26). Rivaroxaban and acetylsalicylic acid was evaluated on Frequency of angina attacks (19.5% decrease, p=0.027). Low-dose rivaroxaban combined with acetylsalicylic acid was associated with a 19.5% decrease in the frequency of angina attacks over 10 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: